MBP and chronic myelogenous leukemia, BCR-ABL1 positive: In order to determine if a three-drug TSR in combination with a TKI leads to improved outcomes over “7 + 3” regimen with a TKI, we conducted a retrospective single-center study of front-line CML-MBP patients.